Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study.
Bloodstream infection
Carbapenem-resistant Acinetobacter baumannii
Cefiderocol
Colistin
Pneumonia
Ventilator-acquired pneumonia
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
18 Apr 2024
18 Apr 2024
Historique:
received:
08
09
2023
accepted:
09
04
2024
medline:
18
4
2024
pubmed:
18
4
2024
entrez:
18
4
2024
Statut:
aheadofprint
Résumé
We assessed the clinical effectiveness of cefiderocol (CFDC) in comparison with colistin (COL) for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections (BSI). Retrospective cohort study including adults with CRAB-BSI. Outcomes were mortality, clinical cure and adverse events during therapy. The average treatment effect of CFDC compared to COL was weighted with the inverse-probability treatment weight (IPTW). Overall, 104 patients were included (50 CFDC, 54 COL), median age 66.5 years, median Charlson Comorbidity Index 5, septic shock in 33.6% of patients. Primary BSI accounted for 43.3% of cases, followed by ventilator-associated pneumonia (VAP) (26%), catheter-related BSI (20.2%) and hospital-acquired pneumonia (HAP) (9.6%). Although not significantly, mortality at all time points was lower for CFDC than COL, while clinical cure was higher in CFDC than COL (66% vs. 44.4%, p = 0.027). Adverse events were more frequent in COL than CFDC-group (38.8% vs. 10%, p < 0.0001), primarily attributed to acute kidney injury (AKI) in the COL group. Patients with bacteremic HAP/VAP treated with CFDC had a significant lower 30-d mortality and higher clinical cure than COL (p = 0.008 and p = 0.0008, respectively). Increment of CCI (p = 0.005), ICU (p = 0.025), SARS-CoV2 (p = 0.006) and ECMO (p < 0.0001) were independently associated with 30-d mortality, while receiving CFDC was not associated with survival. CFDC could represent an effective and safe treatment option for CRAB BSI, especially in patients with bacteremic HAP/VAP and frail patients where the risk of acute renal failure during therapy should be avoided.
Sections du résumé
BACKGROUND
BACKGROUND
We assessed the clinical effectiveness of cefiderocol (CFDC) in comparison with colistin (COL) for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections (BSI).
MATERIALS/METHODS
METHODS
Retrospective cohort study including adults with CRAB-BSI. Outcomes were mortality, clinical cure and adverse events during therapy. The average treatment effect of CFDC compared to COL was weighted with the inverse-probability treatment weight (IPTW).
RESULTS
RESULTS
Overall, 104 patients were included (50 CFDC, 54 COL), median age 66.5 years, median Charlson Comorbidity Index 5, septic shock in 33.6% of patients. Primary BSI accounted for 43.3% of cases, followed by ventilator-associated pneumonia (VAP) (26%), catheter-related BSI (20.2%) and hospital-acquired pneumonia (HAP) (9.6%). Although not significantly, mortality at all time points was lower for CFDC than COL, while clinical cure was higher in CFDC than COL (66% vs. 44.4%, p = 0.027). Adverse events were more frequent in COL than CFDC-group (38.8% vs. 10%, p < 0.0001), primarily attributed to acute kidney injury (AKI) in the COL group. Patients with bacteremic HAP/VAP treated with CFDC had a significant lower 30-d mortality and higher clinical cure than COL (p = 0.008 and p = 0.0008, respectively). Increment of CCI (p = 0.005), ICU (p = 0.025), SARS-CoV2 (p = 0.006) and ECMO (p < 0.0001) were independently associated with 30-d mortality, while receiving CFDC was not associated with survival.
CONCLUSIONS
CONCLUSIONS
CFDC could represent an effective and safe treatment option for CRAB BSI, especially in patients with bacteremic HAP/VAP and frail patients where the risk of acute renal failure during therapy should be avoided.
Identifiants
pubmed: 38634975
doi: 10.1007/s10096-024-04833-8
pii: 10.1007/s10096-024-04833-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Newsroom Antibiotic resistance. World Health Organization [cited 2023 July 23]. https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance
Tacconelli E, Carrara E, Savoldi A et al (2018) Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18(3):318–327. https://doi.org/10.1016/S1473-3099(17)30753-3 Epub 2017 Dec 21. PMID: 29276051
doi: 10.1016/S1473-3099(17)30753-3
pubmed: 29276051
Ayobami O, Willrich N, Suwono B, Eckmanns T, Markwart R (2020) The epidemiology of carbapenem-non-susceptible Acinetobacter species in Europe. Antimicrob Resist Infect Control 9(1):89. https://doi.org/10.1186/s13756-020-00750-5 PMID: 32560670; PMCID: PMC7304165 : analysis of EARS-Net data from 2013 to 2017
Iovleva A, Mustapha MM, Griffith MP et al (2022) Carbapenem-Resistant Acinetobacter baumannii in U.S. hospitals: diversification of circulating lineages and Antimicrobial Resistance. mBio 13(2):e0275921. https://doi.org/10.1128/mbio.02759-21 Epub 2022 Mar 21. PMID: 35311529; PMCID: PMC9040734
doi: 10.1128/mbio.02759-21
pubmed: 35311529
Cavallo I, Oliva A, Pages R et al (2023) Acinetobacter baumannii in the critically ill: complex infections get complicated. Front Microbiol 14:1196774. https://doi.org/10.3389/fmicb.2023.1196774 PMID: 37425994; PMCID: PMC10325864
doi: 10.3389/fmicb.2023.1196774
pubmed: 37425994
pmcid: 10325864
Giacobbe DR, Saffioti C, Losito AR et al (2020) Use of colistin in adult patients: a cross-sectional study. J Glob Antimicrob Resist 20:43–49. https://doi.org/10.1016/j.jgar.2019.06.009 Epub 2019 Jun 15. PMID: 31207379
doi: 10.1016/j.jgar.2019.06.009
pubmed: 31207379
Imberti R, Cusato M, Villani P et al (2010) Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 138(6):1333–1339. https://doi.org/10.1378/chest.10-0463 Epub 2010 Jun 17. PMID: 20558557
doi: 10.1378/chest.10-0463
pubmed: 20558557
Ordooei Javan A, Shokouhi S, Sahraei Z (2015) A review on colistin nephrotoxicity. Eur J Clin Pharmacol 71(7):801–810. https://doi.org/10.1007/s00228-015-1865-4 Epub 2015 May 27. PMID: 26008213
doi: 10.1007/s00228-015-1865-4
pubmed: 26008213
Chen Z, Chen Y, Fang Y et al (2015) Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection. Sci Rep 5:17091. https://doi.org/10.1038/srep17091 PMID: 26597507; PMCID: PMC4657015
doi: 10.1038/srep17091
pubmed: 26597507
pmcid: 4657015
Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N (2018) Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother. ;73(1):22–32. https://doi.org/10.1093/jac/dkx368 . PMID: 29069421
Cai Y, Chai D, Wang R, Liang B, Bai N (2012) Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67(7):1607–1615. https://doi.org/10.1093/jac/dks084 Epub 2012 Mar 22. PMID: 22441575
doi: 10.1093/jac/dks084
pubmed: 22441575
US Food and Drug Administration (2019) Highlights of prescribing information: Fetroja (Cefiderocol). [cited 2023 July 23]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209445s000lbl.pdf
Bassetti M, Echols R, Matsunaga Y et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21(2):226–240. https://doi.org/10.1016/S1473-3099(20)30796-9 Epub 2020 Oct 12. PMID: 33058795
doi: 10.1016/S1473-3099(20)30796-9
pubmed: 33058795
Oliva A, Ceccarelli G, De Angelis M et al (2020) Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii. J Glob Antimicrob Resist 23:292–296 Epub 2020 Oct 13. PMID: 33065329
doi: 10.1016/j.jgar.2020.09.019
pubmed: 33065329
Rando E, Segala FV, Vargas J et al (2021) Cefiderocol for severe carbapenem-resistant A. Baumannii Pneumonia: towards the comprehension of its place in Therapy. Antibiot (Basel) 11(1):3. https://doi.org/10.3390/antibiotics11010003 PMID: 35052880; PMCID: PMC8773286
doi: 10.3390/antibiotics11010003
Bavaro DF, Belati A, Diella L et al (2021) Cefiderocol-based combination therapy for difficult-to-treat Gram-negative severe infections: real-life Case Series and Future perspectives. Antibiot (Basel) 10(6):652. https://doi.org/10.3390/antibiotics10060652 PMID: 34072342; PMCID: PMC8227820
doi: 10.3390/antibiotics10060652
Dalfino L, Stufano M, Bavaro DF et al (2023) Effectiveness of First-Line therapy with Old and Novel antibiotics in Ventilator-Associated Pneumonia caused by Carbapenem-Resistant Acinetobacter baumannii: a real life, prospective, observational, single-center study. Antibiot (Basel) 12(6):1048. https://doi.org/10.3390/antibiotics12061048 PMID: 37370367; PMCID: PMC10295543
doi: 10.3390/antibiotics12061048
Mazzitelli M, Gregori D, Sasset L et al (2023) Cefiderocol-based versus colistin-based regimens for severe carbapenem-resistant Acinetobacter baumannii infections: a propensity Score-Weighted, Retrospective Cohort Study during the first two years of the COVID-19 pandemic. Microorganisms 11(4):984. https://doi.org/10.3390/microorganisms11040984 PMID: 37110408; PMCID: PMC10146662
doi: 10.3390/microorganisms11040984
pubmed: 37110408
pmcid: 10146662
Falcone M, Tiseo G, Nicastro M et al (2021) Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients. Clin Infect Dis. ;72(11):2021–2024. https://doi.org/10.1093/cid/ciaa1410 . PMID: 32941593
Russo A, Bruni A, Gullì S et al (2023) Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19. Int J Antimicrob Agents 62(1):106825. https://doi.org/10.1016/j.ijantimicag.2023.106825 Epub 2023 Apr 21. PMID: 37088438; PMCID: PMC10121149
doi: 10.1016/j.ijantimicag.2023.106825
pubmed: 37088438
pmcid: 10121149
Bavaro DF, Papagni R, Belati A, Diella L, De Luca A, Brindicci G, De Gennaro N, Di Gennaro F, Romanelli F, Stolfa S, Ronga L, Mosca A, Pomarico F, Dell’Aera M, Stufano M, Dalfino L, Grasso S, Saracino A (2023) Cefiderocol Versus Colistin for the treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream infections: a retrospective, propensity-score adjusted, Monocentric Cohort Study. Infect Dis Ther 12(8):2147–2163. https://doi.org/10.1007/s40121-023-00854-6 Epub 2023 Sep 1. PMID: 37653122; PMCID: PMC10505116
doi: 10.1007/s40121-023-00854-6
pubmed: 37653122
pmcid: 10505116
Rando E, Cutuli SL, Sangiorgi F, Tanzarella ES, Giovannenze F, De Angelis G, Murri R, Antonelli M, Fantoni M, De Pascale G (2023) Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. Baumannii ventilator-associated pneumonia: a propensity-weighted cohort study. JAC Antimicrob Resist 5(4):dlad085. https://doi.org/10.1093/jacamr/dlad085 PMID: 37484029; PMCID: PMC10359102
doi: 10.1093/jacamr/dlad085
pubmed: 37484029
pmcid: 10359102
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383. https://doi.org/10.1016/0021-9681(87)90171-8
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
CDC/NHSN Surveillance Definitions for Specific Types of Infections [retrieved October 2022]. https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf
Centers for Disease Control and Prevention website. National Healthcare safety Network (NHSN) Pneumonia (Ventilator-associated [VAP] and non-ventilator-associated Pneumonia [PNEU]) Event. [retrieved January 2023]. https://www.cdc.gov/nhsn/pdfs/pscmanual/6pscvapcurrent.pdf
Cleri DJ, Corrado ML, Seligman SJ (1980) Quantitative culture of intravenous catheters and other intravascular inserts. J Infect Dis 141(6):781–786. https://doi.org/10.1093/infdis/141.6.781
doi: 10.1093/infdis/141.6.781
pubmed: 6993589
Centers for Disease Control and Prevention website. National Healthcare safety Network (NHSN) Bloodstream Infection (BSI) Events. [cited 2022 January 25]. https://www.cdc.gov/nhsn/psc/bsi/index.html
Oliva A, Campogiani L, Savelloni G et al (2023) Clinical characteristics and outcome of Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae infections: a retrospective, observational, 2-Center Clinical Study. Open Forum Infect Dis 10(7):ofad327. https://doi.org/10.1093/ofid/ofad327 PMID: 37476077; PMCID: PMC10354859
doi: 10.1093/ofid/ofad327
pubmed: 37476077
pmcid: 10354859
Mehta RL, Kellum JA, Shah SV et al (2007) Acute kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11(2):R31. https://doi.org/10.1186/cc5713 PMID: 17331245; PMCID: PMC2206446
doi: 10.1186/cc5713
pubmed: 17331245
pmcid: 2206446
Kellum JA, Lameire N, KDIGO AKI Guideline Work Group (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care 17(1):204. https://doi.org/10.1186/cc11454 PMID: 23394211; PMCID: PMC4057151
doi: 10.1186/cc11454
pubmed: 23394211
pmcid: 4057151
EUCAST European Committe on antimicrobial susceptibility testing Website. Clinical breakpoints - breakpoints and guidance January 2 (2023) Clinical breakpoints (v 13.1) - new file for printing (29 June, 2023) to make new breakpoints for anaerobic bacteria available. [cited 2023 July 21]. https://www.eucast.org/clinical_breakpoints
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ Infectious Diseases Society of America Antimicrobial-Resistant Treatment Guidance: Gram-Negative Bacterial Infections. Infectious Diseases Society of America 2023; Version 3.0. [cited 2023 June 18]. https://www.idsociety.org/practice-guideline/amr-guidance/
Tiseo G, Brigante G, Giacobbe DR et al (2022) Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). Int J Antimicrob Agents. ;60(2):106611. https://doi.org/10.1016/j.ijantimicag.2022.106611 . Epub 2022 Jun 11. PMID: 35697179
Paul M, Carrara E, Retamar P et al (2022) European Society of Clinical Microbiology and Infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect 28(4):521–547 Epub 2021 Dec 16. PMID: 34923128
doi: 10.1016/j.cmi.2021.11.025
pubmed: 34923128
Pascale R, Pasquini Z, Bartoletti M et al (2021) Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study. JAC Antimicrob Resist 3(4):dlab174. https://doi.org/10.1093/jacamr/dlab174 PMID: 34806011; PMCID: PMC8599913
doi: 10.1093/jacamr/dlab174
pubmed: 34806011
pmcid: 8599913
Gatti M, Cosentino F, Giannella M, Viale P, Pea F (2023) Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis. Int J Antimicrob Agents. ;63(2):107047. doi: 10.1016/j.ijantimicag.2023.107047. Epub ahead of print. PMID: 38061418
Katsube T, Nicolau DP, Rodvold KA et al (2021) Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. J Antimicrob Chemother 76:2902–2905
doi: 10.1093/jac/dkab280
pubmed: 34383901
pmcid: 8521398
Gatti M, Bartoletti M, Cojutti PG et al (2021) A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol. J Glob Antimicrob Resist 27:294–298 Epub 2021 Oct 26. PMID: 34710630
doi: 10.1016/j.jgar.2021.10.014
pubmed: 34710630
Russo A, Gavaruzzi F, Ceccarelli G et al (2022) Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit. Infection 50:83–92
doi: 10.1007/s15010-021-01643-4
pubmed: 34176088
Cogliati Dezza F, Arcari G, Alessi F et al (2022) Clinical impact of COVID-19 on Multi-drug-resistant Gram-negative Bacilli Bloodstream infections in an intensive care unit setting: two pandemics compared. Antibiot (Basel) 11(7):926. https://doi.org/10.3390/antibiotics11070926 PMID: 35884179; PMCID: PMC9312122
doi: 10.3390/antibiotics11070926
Oliva A, Volpicelli L, Di Bari S et al (2022) Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae: results from a multicentre retrospective study. JAC Antimicrob Resist 4(6):dlac121. https://doi.org/10.1093/jacamr/dlac121 PMID: 36506890; PMCID: PMC9728520
doi: 10.1093/jacamr/dlac121
pubmed: 36506890
pmcid: 9728520
Dhamija A, Thibault D, Fugett J et al (2022) Incremental effect of complications on mortality and hospital costs in adult ECMO patients. Perfusion. ;37(5):461–469. https://doi.org/10.1177/02676591211005697 . Epub 2021 Mar 26. PMID: 33765884
Kühn D, Metz C, Seiler F et al (2020) Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study. Crit Care 24(1):664. https://doi.org/10.1186/s13054-020-03397-1 PMID: 33239110; PMCID: PMC7689974
doi: 10.1186/s13054-020-03397-1
pubmed: 33239110
pmcid: 7689974
Jouffroy R, Parfait PA, Gilbert B et al (2022) Relationship between prehospital modified Charlson Comorbidity Index and septic shock 30-day mortality. Am J Emerg Med 60:128–133 Epub 2022 Aug 6. PMID: 35961123
doi: 10.1016/j.ajem.2022.08.003
pubmed: 35961123
Cogliati Dezza F, Covino S, Petrucci F et al (2023) Risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and related mortality in critically ill patients with CRAB colonization. JAC Antimicrob Resist 5(4):dlad096. https://doi.org/10.1093/jacamr/dlad096
Longshaw SIDERO, Manissero C, Tsuji D, Echols M, Yamano R (2020) In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible gram-negative bacteria from Europe. JAC Antimicrob Resist 2(3):dlaa060. https://doi.org/10.1093/jacamr/dlaa060 PMID: 34223017; PMCID: PMC8210120
doi: 10.1093/jacamr/dlaa060
pubmed: 34223017
pmcid: 8210120
Mushtaq S, Sadouki Z, Vickers A, Livermore DM, Woodford N (2020) Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-negative Bacteria. Antimicrob Agents Chemother 64(12):e01582–e01520. https://doi.org/10.1128/AAC.01582-20 PMID: 32958717; PMCID: PMC767404
doi: 10.1128/AAC.01582-20
pubmed: 32958717
pmcid: 7674041
Wang Y, Li Y, Zhao J, Guan J, Ni W, Gao Z (2022) Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria. Ann Transl Med 10(5):261. https://doi.org/10.21037/atm-22-889 PMID: 35402576; PMCID: PMC8987888
doi: 10.21037/atm-22-889
pubmed: 35402576
pmcid: 8987888
Karakonstantis S, Rousaki M, Kritsotakis EI, Cefiderocol (2022) Systematic review of mechanisms of Resistance, Heteroresistance and in vivo emergence of resistance. Antibiot (Basel) 11(6):723. https://doi.org/10.3390/antibiotics11060723 PMID: 35740130; PMCID: PMC9220290
doi: 10.3390/antibiotics11060723